gene therapy firm’s stock faces cash crunch By Investing.com
Bluebird Bio Inc (NASDAQ:), a biotechnology company specializing in gene therapies for severe genetic diseases and cancer, finds itself at a critical juncture as it navigates financial challenges while striving to bring innovative treatments to market. With a market capitalization of just $61.64 million and a stock price that has declined 77% year-to-date, the company faces significant pressure to execute its strategy effectively. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value model, though investors should note that the company is quickly burning through cash. The company’s focus on launching its product Lyfgenia for sickle cell disease (SCD) has been met with both optimism and caution from…
